Tretinoin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tretinoin: From Acne and Acute Promyelocytic Leukemia to Rheumatoid Nodulosis
One-Sentence Summary
Tretinoin (all-trans retinoic acid) is originally used for acne, acute promyelocytic leukemia, acquired keratosis and palmoplantar keratoderma. The TxGNN model predicts it may be effective for rheumatoid nodulosis, but there are currently 0 clinical trials and 0 relevant publications supporting this direction. This is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne, acute promyelocytic leukemia, acquired keratosis, palmoplantar keratoderma (from the TxGNN knowledge graph; no approved indication text is available from Singapore licences) |
| Predicted New Indication | Rheumatoid nodulosis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, tretinoin is a retinoid that acts through retinoic acid receptor (RAR) signaling. Its efficacy in acne, keratinization disorders and acute promyelocytic leukemia is established. Retinoids are also reported to have immunomodulatory effects, such as influencing the Th17/Treg balance, which could plausibly relate to rheumatoid disease.
This link is a general hypothesis and is not supported by the data compiled for this report. The high TxGNN score reflects a graph-based computational association, not clinical evidence.
The other top predictions are mostly juvenile arthritis entities (ranks 2-4 and 6) and skeletal conditions (ranks 5, 7-9). The juvenile arthritis entries are likely related to one another and do not represent independent signals. Systemic retinoids are known to cause skeletal toxicity, which argues for caution in these areas. Among the top 10, Quinquaud's folliculitis decalvans (rank 10, score 99.30%) is the most biologically plausible, since tretinoin is established in dermatology. It is still an inference rather than evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for rheumatoid nodulosis.
For osteoarthritis (rank 7), two items were retrieved, but neither supports tretinoin use. One concerns platelet-rich plasma injections for knee osteoarthritis. The other is a case report of adverse events after arsenic trioxide treatment for acute promyelocytic leukemia. These are likely retrieval artifacts.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16390P | Tretinon Cream 0.05% w/w | Cream | Not specified |
| SIN08057P | Vesanoid Capsule 10 mg | Capsule | Not specified |
| SIN12368P | Retrieve Cream 0.05% w/w | Cream | Not specified |
| SIN08095P | Retacnyl 0.025 Cream 0.025% | Cream | Not specified |
| SIN08098P | Retacnyl 0.05 Cream 0.05% | Cream | Not specified |
A sixth licence, Tri-Luma Cream (SIN12607P), is also valid. All 6 registrations are single-ingredient and valid. Five are topical creams and one is an oral capsule (Vesanoid).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Differentiation-inducing agent (retinoid) used in acute promyelocytic leukemia, not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Contraindications (knowledge graph, not label text): The TxGNN knowledge graph lists contraindication links with the following conditions:
- Liver, kidney, pancreatic and gallbladder disease
- Congestive heart failure
- Diabetes mellitus and diabetic ketoacidosis
- Adrenocortical insufficiency and Addison disease
- Osteoporosis, including postmenopausal osteoporosis
- Crohn disease and inflammatory bowel disease
- Atopic eczema
- Sunburn
- Psychiatric disorders: anxiety, neurotic, dysthymic, psychotic and schizoaffective disorders
- Mycosis fungoides and related cutaneous T-cell lymphomas
- Drug Interactions: 100 interactions were found. The main Major interactions are:
- Doxycycline
- Tetracycline
- Minocycline
- Vitamin A
Moderate interactions include aprepitant, clarithromycin and naltrexone. Levofloxacin is a minor interaction.
- Other considerations: Systemic tretinoin carries concerns of teratogenicity and bone and mucocutaneous toxicity. These are especially relevant for the pediatric and skeletal predictions.
Package insert warnings and contraindications could not be obtained for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials or relevant literature (Evidence Level L5). The mechanistic link is speculative. The top predictions also overlap with known retinoid skeletal toxicity and with several knowledge graph contraindications.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A targeted literature search on retinoids in rheumatoid nodulosis and related arthritis
- Consideration of dermatological predictions, such as folliculitis decalvans, which may be more plausible than the arthritis and skeletal ones
- Evaluation of route compatibility (topical vs oral) and a risk assessment for systemic exposure
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.